Home > Insider Trading > Filing (0000905148-24-001964)

Filing Details

Accession Number:: 0000905148-24-001964
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-22 20:26:49
Reporting Period:: 2024-07-22

Accepted Time:: 2024-07-22 20:26:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817241	Artiva Biotherapeutics Inc.	ARTV	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278411	S Corey Goodman	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	No	No
1329161	J Robert Adelman	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	No	No
1739920	Venbio Global Strategic Fund Iii, L.p.	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	No	No
1869300	Venbio Global Strategic Gp Iii, Ltd	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	No	No
1869303	Venbio Global Strategic Gp Iii, L.p.	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-07-22	843,592	$0.00	843,592	No	4	C	Direct
Common Stock	Acquisiton	2024-07-22	214,692	$0.00	1,058,284	No	4	C	Direct
Common Stock	Acquisiton	2024-07-22	461,687	$0.00	1,519,971	No	4	J	Direct
Common Stock	Acquisiton	2024-07-22	416,666	$12.00	1,936,637	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	J	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-07-22	843,592	$0.00	843,592	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2024-07-22	214,692	$0.00	214,692	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein.
Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20.